The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 46-55

  Fair, William R ^a   Cookson, Michael S ^a   Stroumbakis, Nicholas ^a   Cohen, David ^a   Aprikian, Armen G ^a   Wang, Yu ^a   Russo, Paul ^a   Soloway, Scott M ^a   Sogani, Pramod ^a   Sheinfeld, Joel ^a   Herr, Harry ^a   Dalgabni, Guido ^a   Begg, Colin B ^a   Heston, Warren D W ^a   Reuter, Victor E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTAMIDE; GONADORELIN; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ANTIGEN DETECTION; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; DRUG THERAPY, COMBINATION; FLUTAMIDE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; PREOPERATIVE CARE; PROSTATIC NEOPLASMS;

EID: 0030966149     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00169-6     Document Type: Conference Paper

References (40)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-27, 1996.
2. Catalona WJ, Richie JP, and Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multi center clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
3. Flanders WD: Review: Prostate cancer epidemiology. Prostate 5: 621-629, 1984.
4. Gibbons RP, Correa RJ, Brannen GE, and Mason JT: Total prostatectomy for localized prostatic cancer. J Urol 131: 73-76, 1984.
5. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tlc) prostate cancer. JAMA 271: 368-374, 1994.
6. Cookson M, Fleshner N, and Fair WR: The Tie prostate cancer. (Submitted to J Urol).
7. Stein A, DeKernion JB, Smith RB, Dorey F, and Patel H: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 147: 942-946, 1992.
8. Morton RM, Steiner PL, and Walsh PC: Cancer control following anatomical radical prostatectomy: an interim report. J Urol 145: 1197-1200, 1991.
9. Frazier HA, Robertson JE, Humphrey PA, and Paulson DF: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 149: 516-518, 1993.
10. Paulson DF, Moul JW, and Walther PJ: Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 144: 1180-1184, 1990.
11. Pinault S, Tetu B, Gagnon J, Monfette G, Dupont A, and Labrie F: Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide. Urology 39: 254-261, 1992.
12. Tetu B, Srigley JR, and Boivin JC, et al: Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: a histopathologic and immunohistochemical study. Am J Surg Pathol 15: 111-120, 1991.
13. Labrie F: Endocrine therapy of prostate cancer. Endocrinol Metab Clin North Am 20: 845-872, 1991.
14. Fair WR, Aprikian A, Sogani P, Reuter V, and Whitmore WF: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 71(suppl): 1031-1038, 1993.
15. Monfette G, Dupont A, and Labrie F: Temporary combination therapy with flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer, in Labrie F, Dupont A (Eds): Early Stage Prostate Cancer: Diagnosis and Choice of Therapy. New York, Excerpta Medica, 1989, pp 41-51.
16. Isaacs JT, and Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostate cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070-5075, 1981.
17. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, and Lawson D: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50: 752-757, 1990.
18. Kennedy TJ, Sonneland AM, Marlett MM, and Troup RH: Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. J Urol 147: 891-893, 1992.
19. Oesterling JE, Andrews PE, Suman VJ, Zincke H, and Myers RP: Pre-operative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 149: 779-782, 1993.
20. Soloway MS, Hachiya T, Civantos F, Murphy WM, Gomez CC, and Ruiz HE: Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer. Urology 43(2): 52-56, 1994.
21. Aprikian AG, Fair WR, Reuter VE, Sogani P, Herr H, Russo P, and Sheinfeld J: Experience with neoadjuvant diethylstilbestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol 74: 630-636, 1994.
22. Sassine AM, and Schulman CC: Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol 24(4): 450-455, 1993 (Erratum appears in Eur Urol 25(3): 247, 1994).
23. Fair WR, Aprikian A, Cohen D, Sogani P, and Reuter V: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med 16: 516-522, 1993.
24. Macfarlene MT, Abi-Aad A, Stein A, Danella J, Belldegrun A, and DeKernion JB: Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 50: 132-134, 1993.
25. Solomon MH, McHugh TA, Dorr RP, Lee F, and Siders DB: Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy. Clin Invest Med 16(6): 532-538, 1993.
26. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, and Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 154: 424-428, 1995.
27. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, and Pavone-Macaluso M: The TMN classification of prostate cancer. Prostate 4: 129-138, 1992.
28. Labrie F, Dupont A, and Cusan L, et al: Downstaging of localized prostate cancer by neo-adjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 16(6): 499-509, 1993.
29. Eschwege P, Dumas F, Blanchet P, Le Maire V, Benoit G, Jardin A, Lacour B, and Loric S: Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 346: 1528-1530, 1995.
30. Fair WR, Israeli RS, Wang Y, Nawabi MD, Edwards ET, and Heston WDW: Neoadjuvant androgen-deprivation therapy (ADT) prior to radical prostatectomy results in a significantly decreased incidence of residual micrometastatic disease as detected by nested RT-PCR with PSM primers. J Urol 153: 391a, 1995.
31. Rosen MA, Goldstone L, Lapin S, Wheeler T, and Scardino PT: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 148: 331-337, 1992.
32. 2c or lower) prostate cancer. J Urol 152: 1850-1857, 1994.
33. Murphy GP, Mettlin C, Menk H, Winchester DP, and Davidson AM: National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 152: 1817-1819, 1994.
34. Walsh PC, Partin AW, and Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152: 1831-1836, 1994.
35. Catalona WJ, and Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152: 1837-1842, 1994.
36. Bostwick DG, Myers RP, and Oesterling JE: Staging of prostate cancer. Semin Surg Oncol 10: 60-72, 1994.
37. Paulson DP: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152: 1826-1830, 1994.
38. Van Poppel H, Ameye F, Oyen R, Van de Voorde W, and Baert L: Radical prostatectomy for localized prostate cancer. Eur J Surg Oncol 18: 456-462, 1992.
39. Andros EA, Danesghari F, and Crawford ED: Neoadjuvant hormonal therapy in stage C adenocarcinoma of the prostate. Clin Invest Med 16: 510-515, 1993.
40. 2 prostate cancer: interim results of a prospective randomized trial. J Urol 154: 429-434, 1996.